Is Dr. Reddy's Laboratories Limited (RDY) Overvalued?
We dive into why Dr. Reddy's Laboratories Limited (RDY) could be considered overvalued on 2026-07-23, based on AAII’s Value Score and Grade.Rosalio Madrigal
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Jenna Brashear
Jenna Brashear
Jenna Brashear
Michael Rose
| Share Statistics | RDY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $10,181.2 | $674.5 | 78% |
|
| Shares Out (Mil) | 8.8 | 43.5 | 19% |
|
| Institutional Ownership | 68.5% | 84.6% | 42% |
|
| Float (Mil) | 600.0 | 47.3 | 87% |
|
| Beta | 0.26 | 0.71 | 16% |
|
| Avg Daily Volume (000s) | 2,386 | 290 | 86% |
|
| Price Change (52-week) |
(15.4%) | 69.3% | 33% |
|
| Growth | RDY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 6.7% | 6.7% | 44% |
|
| Net Income (5yr) | 14.2% | (1.4%) | 62% |
|
| EPS (5yr) | 14.1% | 15.0% | 54 |
|
| Dividends (5yr) | 4.5% | 0.0% | 56% |
|
| Cash Flow (5yr) | (43.0%) | (15.0%) | 10% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | RDY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3,503 | $317 | 69% |
|
| Net Income (TTM) (Mil) | $350 | ($11) | 74% |
|
| EPS (TTM) | $0.420 | ($0.700) | 52% |
|
| Operating Cash Flow (TTM) (Mil) | $436 | ($6) | 69% |
|
| Net Cash Flow (TTM) (Mil) | $28 | $5 | 65% |
|
| Long-Term Debt (Q1) (Mil) | $126 | $6 | 46% |
|
| Enterprise Value (Q1) (Mil) | $10,089 | $536 | 74% |
|
| Valuation | RDY | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.46 | 2.80 | 58% |
|
| P/E | 28.5 | 17.1 | 68% |
|
| Dividend Yield | 0.7% | 0.0% | 64% |
|
| PEG (5yr hist) | 2.0 | 1.1 | 68% |
|
| Ratios | RDY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 50.2% | 68.1% | 62% |
|
| Net Margin | 10.0% | (1.4%) | 63% |
|
| ROA | 5.8% | (24.1%) | 75% |
|
| ROE | 8.6% | (21.0%) | 53% |
|
| Liabilities to Assets | 32.8% | 32.3% | 24% |
|
| F-Score | 5 | 3 | 50% |
|
Dr. Reddy's Laboratories Limited did not pass any screens on 9/4/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors